Published in Arthritis Rheum on May 01, 1997
ICAM-1 as a molecular target for triple negative breast cancer. Proc Natl Acad Sci U S A (2014) 0.96
The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis (2015) 0.91
Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis. Ann Rheum Dis (2003) 0.84
An innovative method to identify autoantigens expressed on the endothelial cell surface: serological identification system for autoantigens using a retroviral vector and flow cytometry (SARF). Clin Dev Immunol (2013) 0.80
Heparin Attenuates the Expression of TNFalpha-induced Cerebral Endothelial Cell Adhesion Molecule. Korean J Physiol Pharmacol (2008) 0.78
Where is biological therapy going? Arthritis Res (2000) 0.77
Hypoxia-Inducible Factor (HIF) as a Target for Novel Therapies in Rheumatoid Arthritis. Front Pharmacol (2016) 0.76
Changes in Soluble CD18 in Murine Autoimmune Arthritis and Rheumatoid Arthritis Reflect Disease Establishment and Treatment Response. PLoS One (2016) 0.75
Cyclooxygenase in biology and disease. FASEB J (1998) 7.17
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA (1999) 4.25
Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J Immunol (1995) 3.31
Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol (2001) 3.07
Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol (2000) 3.05
Phenotype of the accessory cell necessary for mitogen-stimulated T and B cell responses in human peripheral blood: delineation by its sensitivity to the lysosomotropic agent, L-leucine methyl ester. J Immunol (1983) 3.04
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes. J Immunol (1991) 2.69
Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(-)/IgM+ B cells. J Clin Invest (1997) 2.44
Macrophage-lymphocyte interaction. II. Antigen-mediated physical interactions between immune guinea pig lymph node lymphocytes and syngeneic macrophages. J Exp Med (1975) 2.44
Monocyte dependence of pokeweed mitogen-induced differentiation of immunoglobulin-secreting cells from human peripheral blood mononuclear cells. J Immunol (1979) 2.36
Isolation and characterization of human peripheral blood dendritic cells. J Immunol (1993) 2.33
The role of cell surface recognition structures in the initiation of MHC-unrestricted 'promiscuous' killing by T cells. Immunol Today (1989) 2.31
Antigen presentation by interferon-gamma-treated endothelial cells and fibroblasts: differential ability to function as antigen-presenting cells despite comparable Ia expression. J Immunol (1985) 2.27
The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. Arthritis Rheum (1994) 2.26
Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol (2000) 2.17
Accessory cell independent proliferation of human T4 cells stimulated by immobilized monoclonal antibodies to CD3. J Immunol (1987) 2.03
Macrophage-lymphocyte interaction. I. Characteristics of the antigen-independent-binding of guinea pig thymocytes and lymphocytes to syngeneic macrophages. J Exp Med (1973) 2.00
Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells. J Immunol (1987) 1.97
Circulating and mitogen-induced immunoglobulin-secreting cells in human peripheral blood: evaluation by a modified reverse hemolytic plaque assay. J Immunol (1978) 1.93
[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]. Z Rheumatol (2012) 1.91
Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum (1988) 1.90
Inhibition of antigen- and mitogen-induced human lymphocyte proliferation by gold compounds. J Clin Invest (1977) 1.89
Regulation of calcium signalling in T lymphocytes by the second messenger cyclic ADP-ribose. Nature (1999) 1.86
Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides activate monocytes/macrophages. J Immunol (1995) 1.86
Enrichment of differentiated CD45RBdim,CD27- memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum (1996) 1.85
Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol (2001) 1.85
Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules. J Immunol (1990) 1.83
Analysis of the frequency and pattern of somatic mutations within nonproductively rearranged human variable heavy chain genes. J Immunol (1997) 1.80
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum (1998) 1.79
The four biochemically distinct species of human interleukin 1 all exhibit similar biologic activities. J Immunol (1985) 1.78
Circulating and pokeweed mitogen-induced immunoglobulin-secreting cells in systemic lupus erythematosus. Clin Exp Immunol (1979) 1.74
Experience in monitoring drug reactions in outpatients. The Kaiser-Permanente Drug Monitoring System. JAMA (1971) 1.71
Enhancement of antigen- and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor-alpha. J Immunol (1988) 1.71
Leukocyte function-associated antigen 1 is an activation molecule for human T cells. J Exp Med (1989) 1.69
Human peripheral blood dendritic cell subsets. Isolation and characterization of precursor and mature antigen-presenting cells. J Immunol (1994) 1.67
Decay-accelerating factor functions as a signal transducing molecule for human T cells. J Immunol (1988) 1.67
Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol (1997) 1.66
Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1. J Immunol (1987) 1.66
Spontaneous and induced membrane hyperpolarizations in macrophages. J Cell Physiol (1975) 1.64
Regulation of cellular function by products of lysosomal enzyme activity: elimination of human natural killer cells by a dipeptide methyl ester generated from L-leucine methyl ester by monocytes or polymorphonuclear leukocytes. Proc Natl Acad Sci U S A (1985) 1.63
Migration of naive and memory T cells. Immunol Today (1997) 1.62
Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis. Arthritis Rheum (1990) 1.61
Erythromelanosis follicularis faciei in women. J Am Acad Dermatol (1995) 1.61
The role of cytokines in the pathogenesis of rheumatoid arthritis. Springer Semin Immunopathol (1989) 1.57
Activation of human B cells by phosphorothioate oligodeoxynucleotides. J Clin Invest (1996) 1.57
Mechanism of L-leucyl-L-leucine methyl ester-mediated killing of cytotoxic lymphocytes: dependence on a lysosomal thiol protease, dipeptidyl peptidase I, that is enriched in these cells. Proc Natl Acad Sci U S A (1990) 1.56
Molecular mechanisms and selective influences that shape the kappa gene repertoire of IgM+ B cells. J Clin Invest (1997) 1.52
Human expression recognition from motion using a radial basis function network architecture. IEEE Trans Neural Netw (1996) 1.51
Human T lymphocyte adhesion to endothelial cells and transendothelial migration. Alteration of receptor use relates to the activation status of both the T cell and the endothelial cell. J Immunol (1990) 1.51
Interleukin 15 is produced by endothelial cells and increases the transendothelial migration of T cells In vitro and in the SCID mouse-human rheumatoid arthritis model In vivo. J Clin Invest (1998) 1.50
Chronic non-bacterial osteomyelitis in children. Ann Rheum Dis (2005) 1.49
The role of interleukin 1 in human B cell activation: inhibition of B cell proliferation and the generation of immunoglobulin-secreting cells by an antibody against human leukocytic pyrogen. J Immunol (1983) 1.49
Inhibitory influence of IL-4 on human B cell responsiveness. J Immunol (1988) 1.48
Generation of active myeloid and lymphoid granule serine proteases requires processing by the granule thiol protease dipeptidyl peptidase I. J Biol Chem (1993) 1.48
Infliximab in active early rheumatoid arthritis. Ann Rheum Dis (2004) 1.47
The immunosuppressive activity of L-leucyl-L-leucine methyl ester: selective ablation of cytotoxic lymphocytes and monocytes. J Immunol (1986) 1.46
The CD40 ligand expressed by human B cells costimulates B cell responses. J Immunol (1995) 1.46
Immunoglobulin kappa chain receptor editing in systemic lupus erythematosus. J Clin Invest (1998) 1.45
Phytohemagglutinin-induced proliferation of guinea pig thymus-derived lymphocytes. I. Accessory cell dependence. J Immunol (1976) 1.45
Modulation of human natural killer cell function by L-leucine methyl ester: monocyte-dependent depletion from human peripheral blood mononuclear cells. J Immunol (1985) 1.44
Macrophage-lymphocyte interaction and antigen recognition. Fed Proc (1975) 1.44
Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus (2004) 1.43
Relationship between clinical efficacy and laboratory correlates of inflammatory and immunologic activity in rheumatoid arthritis patients treated with nonsteroidal antiinflammatory drugs. Arthritis Rheum (1990) 1.43
Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells. J Immunol (1994) 1.43
Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum (1995) 1.42
The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol (2007) 1.41
Control of human B lymphocyte responsiveness: enhanced suppressor T cell activity after in vitro incubation. J Immunol (1978) 1.41
Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum (1994) 1.41
T cell-dependent activation of B cell proliferation and differentiation by immobilized monoclonal antibodies to CD3. J Immunol (1988) 1.41
The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am (2000) 1.39
A phase I study of ethyl acetate extract of the chinese antirheumatic herb Tripterygium wilfordii hook F in rheumatoid arthritis. J Rheumatol (2001) 1.39
Accessory cell signals involved in T-cell activation. Immunol Rev (1990) 1.37
Regulation of human B lymphocyte activation, proliferation, and differentiation. Adv Immunol (1987) 1.35
Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. Eur J Immunol (1998) 1.35
Cutting edge: stromal cell-derived factor-1 is a costimulator for CD4+ T cell activation. J Immunol (2000) 1.35
Role of CD11/CD18 in adhesion and transendothelial migration of T cells. Analysis utilizing CD18-deficient T cell clones. J Immunol (1991) 1.34
Cimetidine-associated exacerbation of cutaneous lupus erythematosus. Arch Intern Med (1982) 1.34
Clinical significance of increased CD4+CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus. Ann Rheum Dis (2008) 1.33
Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J Clin Invest (1997) 1.32
Human endothelial cell-lymphocyte interaction. Endothelial cells function as accessory cells necessary for mitogen-induced human T lymphocyte activation in vitro. J Clin Invest (1981) 1.31
Dissection of defective antigen presentation by interferon-gamma-treated fibroblasts. J Immunol (1987) 1.29
Delineation of the mechanism of inhibition of human T cell activation by PGE2. J Immunol (1990) 1.28
Association of various T cell-surface molecules with the cytoskeleton. Effect of cross-linking and activation. J Immunol (1991) 1.28
European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus (2009) 1.28
Signals involved in T cell activation. II. Distinct roles of intact accessory cells, phorbol esters, and interleukin 1 in activation and cell cycle progression of resting T lymphocytes. J Immunol (1986) 1.27
Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J Immunol (1995) 1.27